Explore 3 Stock Ideas & Industry Insights Download Free Report

News

LLY Stock Surges as Novo Nordisk’s CagriSema Trial Misses Zepbound

Shares of Eli Lilly and Company moved higher after reports indicated that Novo Nordisk’s investigational obesity therapy CagriSema did not outperform Zepbound in comparative clinical data. The market reaction underscores how tightly equity valuations in the pharmaceutical sector are now linked to incremental clinical …

Nitish Kishor | 23 February 2026

WTI Crude Oil Near Six-Month High as US–Iran Nuclear Talks and Strait of Hormuz Risks Drive Global Oil Market Volatility

WTI crude oil futures hovered around $66.5 per barrel on Monday, close to a six-month high, as financial markets weighed two competing forces: the prospect of renewed US–Iran nuclear diplomacy and the residual risk of military escalation in the Middle East. The balance between …

Nitish Kishor | 23 February 2026

Markets Turn Cautious Amid Escalating Tariff Measures and Geopolitical Tensions

Market Movers:On Friday, the top gainers were Abits Group Inc (+86.49%), followed by RingCentral, Inc. (+34.40%). On the contrary, GRAIL, Inc. (-50.55%), and WeShop Holdings Limited (-45.05%) declined the most the same day.

Team Kalkine | 23 February 2026

Nvidia Earnings in Focus Amid a High-Stakes Macro Environment

Nvidia reports fiscal fourth-quarter results after the bell on February 25, with consensus expectations pointing to revenue of roughly $65bn and earnings per share of $1.52. That would mark a sharp year-on-year expansion, reflecting sustained demand for artificial intelligence infrastructure and high-performance computing.

Nitish Kishor | 23 February 2026

Bullish (NYSE:BLSH) Rating Upgrade to “Hold” Comes Amid Earnings Miss and Mixed Targets

Bullish (NYSE:BLSH) has moved from a “sell” to a “hold” rating at Wall Street Zen, marking a notable adjustment in coverage. Across the broader analyst landscape, sentiment remains distributed, with five “buy,” seven “hold,” and one “sell” rating recorded, resulting in a consensus “Hold,” …

Aditi Sarkar | 23 February 2026

Tariff Move and Middle East Tensions Weigh on Wall Street Outlook

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Aditi Sarkar | 23 February 2026

Apple Resets Narrative as Investors Reassess Growth, Cash, and AI Potential

Apple (NASDAQ:AAPL) has forced Wall Street into a fresh debate: is the stock still a must-own growth leader or a cash-rich compounder trading at a premium? The latestearningssignals, evolvingrevenuemix, and rising regulatory scrutiny are pushing investors to rethink how the tech heavyweight fits into …

Aditi Sarkar | 23 February 2026

Tariff Twist Lifts Sentiment as Inflation Data and Nvidia Take Centre Stage

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Aditi Sarkar | 23 February 2026

Cemig (NYSE:CIG) Stock Climbs Again: Should Investors Worry About the Sell Rating?

Shares of Companhia Energética de Minas Gerais (NYSE:CIG) are trading at USD 2.30, marking a 2.22% increase in the latest session. Over the past five trading days, the stock has risen 4.07%, while the one-month performance shows a 7.48% gain.

Team Kalkine | 22 February 2026

Telix Pharmaceuticals (NASDAQ:TLX) Falls After Results — Time to Reconsider the Buy Rating?

Telix Pharmaceuticals (NASDAQ:TLX) reported quarterlyearnings per shareof USD -0.01, compared with market expectations of USD 0.05, representing a shortfall of USD 0.06. Quarterly revenue came in at USD 413.4M, below the consensus estimate of USD 421.5M.

Team Kalkine | 22 February 2026
Support

Hi! How can we help you today?

Loading…